At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 204 enrolled
Drug / intervention
Ixekizumab Auto-Injector +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab Auto-Injector and Ixekizumab Prefilled Syringe for Plaque Psoriasis. Completed, enrolled 204 participants across 25 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartMar 2013
Primary CompletionMay 2014
Study CompletionMay 2015
TodayJul 2026
First PostedJan 28, 2013
Enrollment StartMar 1, 2013
Primary CompletionMay 1, 2014
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.4 years ago
Interventions
Ixekizumab Auto-Injectordrug
Administered SC by auto-injector
Ixekizumab Prefilled Syringedrug
Administered SC by prefilled syringe